212 related articles for article (PubMed ID: 15166378)
21. Cellular protein is the source of cross-priming antigen in vivo.
Shen L; Rock KL
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3035-40. PubMed ID: 14978273
[TBL] [Abstract][Full Text] [Related]
22. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
23. Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming.
Zehn D; Cohen CJ; Reiter Y; Walden P
Int Immunol; 2006 Dec; 18(12):1647-54. PubMed ID: 17035346
[TBL] [Abstract][Full Text] [Related]
24. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
[TBL] [Abstract][Full Text] [Related]
25. Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter by CD8(+) T cells.
Riond J; Elhmouzi J; Hudrisier D; Gairin JE
Scand J Immunol; 2007 Oct; 66(4):441-50. PubMed ID: 17850589
[TBL] [Abstract][Full Text] [Related]
26. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
Sotiriadou NN; Kallinteris NL; Gritzapis AD; Voutsas IF; Papamichail M; von Hofe E; Humphreys RE; Pavlis T; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2007 May; 56(5):601-13. PubMed ID: 16960693
[TBL] [Abstract][Full Text] [Related]
27. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain.
Lizée G; Basha G; Tiong J; Julien JP; Tian M; Biron KE; Jefferies WA
Nat Immunol; 2003 Nov; 4(11):1065-73. PubMed ID: 14566337
[TBL] [Abstract][Full Text] [Related]
28. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
Gasteiger G; Kastenmuller W; Ljapoci R; Sutter G; Drexler I
J Virol; 2007 Nov; 81(21):11925-36. PubMed ID: 17699574
[TBL] [Abstract][Full Text] [Related]
29. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.
Huckriede A; Bungener L; Holtrop M; de Vries J; Waarts BL; Daemen T; Wilschut J
Vaccine; 2004 Mar; 22(9-10):1104-13. PubMed ID: 15003637
[TBL] [Abstract][Full Text] [Related]
30. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
32. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance.
Limmer A; Ohl J; Wingender G; Berg M; Jüngerkes F; Schumak B; Djandji D; Scholz K; Klevenz A; Hegenbarth S; Momburg F; Hämmerling GJ; Arnold B; Knolle PA
Eur J Immunol; 2005 Oct; 35(10):2970-81. PubMed ID: 16163670
[TBL] [Abstract][Full Text] [Related]
33. The cross-priming pathway: a portrait of an intricate immune system.
Basta S; Alatery A
Scand J Immunol; 2007 Apr; 65(4):311-9. PubMed ID: 17386021
[TBL] [Abstract][Full Text] [Related]
34. IRAP identifies an endosomal compartment required for MHC class I cross-presentation.
Saveanu L; Carroll O; Weimershaus M; Guermonprez P; Firat E; Lindo V; Greer F; Davoust J; Kratzer R; Keller SR; Niedermann G; van Endert P
Science; 2009 Jul; 325(5937):213-7. PubMed ID: 19498108
[TBL] [Abstract][Full Text] [Related]
35. Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles.
Keller SA; von Allmen CE; Hinton HJ; Bauer M; Muntwiler S; Dietmeier K; Saudan P; Bachmann MF
J Immunol; 2009 May; 182(10):6261-6. PubMed ID: 19414779
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
[TBL] [Abstract][Full Text] [Related]
37. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
[TBL] [Abstract][Full Text] [Related]
38. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells.
Uhl M; Kepp O; Jusforgues-Saklani H; Vicencio JM; Kroemer G; Albert ML
Cell Death Differ; 2009 Jul; 16(7):991-1005. PubMed ID: 19229247
[TBL] [Abstract][Full Text] [Related]
39. Viral interference with antigen presentation.
Yewdell JW; Hill AB
Nat Immunol; 2002 Nov; 3(11):1019-25. PubMed ID: 12407410
[TBL] [Abstract][Full Text] [Related]
40. Effective Priming of Herpes Simplex Virus-Specific CD8
Whitney PG; Makhlouf C; MacLeod B; Ma JZ; Gressier E; Greyer M; Hochheiser K; Bachem A; Zaid A; Voehringer D; Heath WR; Wagle MV; Parish I; Russell TA; Smith SA; Tscharke DC; Gebhardt T; Bedoui S
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
